Non-alcoholic Fatty Liver Disease in Children

Muzurović, Emir; Polyzos, Stergios A.; Mikhailidis, Dimitri P.; Borozan, Sanja; Novosel, Dušanka; Cmiljanić, Oleg; Kadić, Nataša; Mantzoros, Christos S.

doi:10.2174/1570161121666221118155136

Cited by 12 publications

(5 citation statements)

References 232 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity is preventable and researchers want to explore the effects of GLP-1 in lowering body weight, body fat and improving metabolic features among pediatric participants. 55 This study evaluates the efficacy of this medication as a possible treatment approach for childhood obesity. As expected, the reasons for GLP-1 usage for obesity were involved with its mechanism and GLP-1 receptor activity, especially its non-glycemic effects and its benefits regarding comorbidity related with insulin resistance.…”

Section: Discussionmentioning

confidence: 99%

Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov

Alorfi,

Alshehri

2023

JMDH

View full text Add to dashboard Cite

Background: Obesity in both adults and children is a primary health concern that can lead to many complications at a young age, including insulin resistance, type 2 diabetes, and other diseases. Glucagon-like peptide-1 receptor agonists (GLP-1) are drugs utilized to treat diabetes, but they are also approved as an adjunct to a low-calorie diet to reduce body weight and to enhance the metabolic profile readings for diabetic and non-diabetic patients. However, their efficacy and safety in children have not been extensively examined. Aim: To identify glucagon-like peptide-1 medications for obesity in pediatric participants (aged up to 17 years old). Methods: Analysis of all clinical trials registered on ClinicalTrials.gov for obesity using GLP-1 as a treatment for children. Results: As of January 26th, 2023, 10,828 clinical trials were found. The search included childhood obesity using GLP-1. The number of trials on the use of GLP-1 to treat childhood obesity is limited. The final number of analyzed trials was 19. GLP-1 has been shown to result in the effective management of body gain among children. Conclusion: Exenatide, semaglutide, and liraglutide were the only GLP-1 medications used as the pharmacotherapy option. It has been studied in many circumstances eg, to treat children with severe obesity, PCOS, hypothalamic obesity, glucose tolerance, and as a complementary treatment alongside behavior-lifestyle change and surgery for obesity.

show abstract

Section: Discussionmentioning

confidence: 99%

Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov

Alorfi,

Alshehri

2023

JMDH

View full text Add to dashboard Cite

show abstract

“…However, this equilibrium is thrown off in obese people 59 . The released adipokines change, heading towards an additional steatogenic, inflammatory, and fibrogenic character as the adipose tissue enlarges 60 . Adipokines interact with immune cells (macrophages, B-lymphocytes, T-lymphocytes, and neutrophils), which invade adipose tissue during its expansion and produce interleukins (ILs) and classical cytokines such as IL-1, IL-6, and tumor necrosis factor (TNF alpha) 61 .…”

Section: B Effects Of Obesity On Hepatic Pathophysiologymentioning

confidence: 99%

Diverted Mini Gastric Bypass Surgery in Obese Population: Out-turn Over Hepatic and Nephrological Parameters

Singh,

Ahmad,

Sinha

et al. 2023

Bangladesh J Med Sci

View full text Add to dashboard Cite

Introduction: Bariatric surgery is the best possible option for reducing weight when lifestyle changes and medication have not brought about lasting success and may reduce morbidity and mortality. Weight loss that may follow bariatric surgery in patients on calory restricted diet would result in reduced inflammation and therefore lowering inflammation-related organ damage, including that of the kidney and liver. The study aimed to observe the consequences of BMI change on Hepatic and Nephrological parameters in patients after One Anastomosis Gastric Bypass surgery. Method: This study was done at a bariatric center with 150 individuals (both male and female) aged 20 to 60 years with obesity grades II and III who were selected randomly. Hepatic and renal function tests were carried out at baseline visit, then 3 months and 6 months following surgically. Result: Bilirubin level significantly increased from baseline to visit 1; Serum glutamic-pyruvic transaminase (SGPT) levels significantly decreased at visits 1 and 2. The albumin to Globulin ratio was significantly increased at visit 2 . Blood Urea level and serum creatinine level reduced considerably at visit 1 and decreased more at visit 2 from baseline. Conclusion: Bariatric surgery may be related to improvement in both hepatic and renal function. The improvement may be attributed to reduced inflammatory organ damage related to obesity. More such studies must be performed to highlight the possible health benefits of bariatric surgery for obese patients whose lifestyle modification and medication have not aided in weight loss. Bangladesh Journal of Medical Science Vol. 22 No. 04 October’23 Page : 743-758

show abstract

“…NAFLD has also become the most common liver disease in children and adolescents, which may lead to serious implications, including both intra-hepatic and extra-hepatic morbidities, such as cardiovascular disease and cancer [ 26 ]. Fat accumulation, insulin resistance, gut-liver axis dysfunction, dietary factors, and genetic factors, including patatin like phospholipase domain containing 3, glucokinase regulator protein, apolipoprotein C-III, transmembrane 6 superfamily 2, and peroxisome proliferator-activated receptor gamma coactivator 1-alpha, are considered factors that are associated with the pathogenesis of NAFLD in children [ 27 , 28 ].…”

Section: Pathogenesis Of Nafldmentioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia

Lim¹,

Jeong²,

Hong³

et al. 2023

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to increase to over half of the adult population by 2040 globally. Since the final diagnosis of NAFLD is made by a liver biopsy, several non-invasive approaches have been developed and validated to define NAFLD and evaluate NAFLD-associated diseases. Presently, NAFLD has been identified as an important and independent risk factor for developing several extrahepatic diseases, including atherosclerosis, cardiovascular disease (CVD), diabetes, and dementia. This review discusses current findings of up-to-date literature regarding the effects of NAFLD on the risk of atherosclerosis and CVD in Asia along with potential underlying biological mechanisms and therapeutic approaches to lower the NAFLD-related CVD risk. We further focus on the difference between NAFLD and metabolic dysfunction-associated fatty liver disease (MAFLD) on the risk of CVD and its implication by comparing the risk of NAFLD and MAFLD.

show abstract

Non-alcoholic Fatty Liver Disease in Children

Cited by 12 publications

References 232 publications

Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov

Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov

Diverted Mini Gastric Bypass Surgery in Obese Population: Out-turn Over Hepatic and Nephrological Parameters

Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia

Contact Info

Product

Resources

About